Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients

Journal of Immunotherapy

Volumn 33, Issue 8, 2010, Pages 848-858

  Speiser, Daniel E ^a   Schwarz, Katrin ^b   Baumgaertner, Petra ^a   Manolova, Vania ^b   Devevre, Estelle ^a   Sterry, Wolfram ^g   Walden, Peter ^g   Zippelius, Alfred ^c   Conzett, Katrin Baumann ^d   Senti, Gabriela ^e   Voelter, Verena ^f   Cerottini, Jean Philippe ^f   Guggisberg, David ^f   Willers, Jörg ^b   Geldhof, Christine ^a   Romero, Pedro ^a   Kündig, Thomas ^d   Knuth, Alexander ^d   Dummer, Reinhard ^d   Trefzer, Uwe ^g   Bachmann, Martin F ^b   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b CYTOS BIOTECHNOLOGY AG   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e InterCorNet   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CD8 T cells; melan A Mart 1; vaccination; virus like nanoparticles

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 2; MELAN A; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ARTHRALGIA; ARTICLE; CANCER STAGING; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN CELL; MALE; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; MYALGIA; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS LIKE AGENT; VOMITING;

ADULT; AGED; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MALE; MART-1 ANTIGEN; MELANOMA; MICE; MICE, TRANSGENIC; MIDDLE AGED; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; VACCINES, VIRUS-LIKE PARTICLE;

EID: 77958051699     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181f1d614     Document Type: Article

References (32)

1. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol. 2001;13:134-140.
2. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human t cells. Immunol Rev. 2002;188:51-64.
3. Parmiani G, De Filippo A, Novellino L, et al. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol. 2007;178:1975-1979.
4. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphode-pleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23: 2346-2357.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
6. Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38:1404-1413.
7. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human cd8+ t cell responses to vaccination with peptide, ifa, and cpg oligodeoxynucleotide 7909. J Clin Invest. 2005;115:739-746.
8. Bachmann MF, Beerli RR, Agnellini P, et al. Long-lived memory cd8+ t cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur J Immunol. 2006;36:842-854.
9. Hofbauer GF, Kamarashev J, Geertsen R, et al. Melan a/mart-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998;8:337-343.
10. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the mart-1 human melanoma antigen recognized by the majority of hla-a2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180:347-352.
11. Valmori D, Fonteneau JF, Maranon Lizana C, et al. Enhanced generation of specific tumor-reactive ctl in vitro by selected melan-a/mart-1 immunodominant peptide analogs. J Immunol. 1998;160:1750-1758.
12. Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective b cell responses. Vaccine. 2002;20:3104-3112.
13. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific t lymphocytes. Science. 1996;274: 94-96.
14. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naive melan-a/mart-1-specific cd8+ t cells in a large proportion of human histocompatibility leukocyte antigen (hla)-a2 individuals. J Exp Med. 1999;190:705-715.
15. Itano AA, McSorley SJ, Reinhardt RL, et al. Distinct dendritic cell populations sequentially present antigen to cd4 t cells and stimulate different aspects of cell-mediated immunity. Immunity. 2003;19:47-57.
16. Speiser DE, Pittet MJ, Guillaume P, et al. Ex vivo analysis of human antigen specific cd8+ t cell responses: quality assessment of fluorescent hla-a2 multimers and ifn gamma elispot assays for patient immune monitoring. J Immunother. 2004; 27:298-308.
17. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic t cells. Nat Med. 2003; 9:1377-1382.
18. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory t lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
19. Lienard D, Rimoldi D, Marchand M, et al. Ex vivo detectable activation of melan-a specific t cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in ifa. Cancer Immun. 2004;4:4.
20. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
21. Petrilli V, Dostert C, Muruve DA, et al. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007;19:615-622.
22. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
23. Storni T, Ruedl C, Renner WA, et al. Innate immunity together with duration of antigen persistence regulate effector t cell induction. J Immunol. 2003;171:795-801.
24. Bachmann MF, Oxenius A, Pircher H, et al. Tap1-independent loading of class i molecules by exogenous viral proteins. Eur J Immunol. 1995;25:1739-1743.
25. Sedlik C, Dadaglio G, Saron MF, et al. In vivo induction of a high-avidity, high-frequency cytotoxic t-lymphocyte response is associated with antiviral protective immunity. J Virol. 2000; 74:5769-5775.
26. Kovacsovics-Bankowski M, Clark K, Benacerraf B, et al. Efficient major histocompatibility complex class i presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci \USA. 1993;90:4942-4946.
27. Romero P, Cerottini JC, Speiser DE. The human t cell response to melanoma antigens. Adv Immunol. 2006;92:187-224.
28. Gallimore A, Dumrese T, Hengartner H, et al. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic t cell responses to naturally processed peptides. J Exp Med. 1998;187:1647-1657.
29. Sacre K, Carcelain G, Cassoux N, et al. Repertoire, diversity, and differentiation of specific cd8 t cells are associated with immune protection against human cytomegalovirus disease. J Exp Med. 2005;201:1999-2010.
30. Zinkernagel RM, Hengartner H. Protective "immunity" by pre-existent neutralizing antibody titers and preactivated t cells but not by so-called "immunological memory". Immunol Rev. 2006;211:310-319.
31. Williams MA, Holmes BJ, Sun JC, et al. Developing and maintaining protective cd8+ memory t cells. Immunol Rev. 2006;211:146-153.
32. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self antigen triggers human cd8 t cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci \USA. 2008;105:3849-3854.